Pharmacology Research & Perspectives is the outlet for fundamental and applied pharmacology. An official journal of the American Society for Pharmacology and Experimental Therapeutics and the British Pharmacological Society this gold open access journal publishes original research, reviews and perspectives in all areas of preclinical and clinical pharmacology, education and related research areas including articles that disprove a hypothesis.

• Provides scientific information and product education to health care professionals in subjects related to therapeutic areas, disease states, and clinical product development and life cycle management • Plays key role in developing the field medical affairs strategy for marketed products and compounds in the Alkermes pipeline

New career trajectory as member of Lundbeck Medical Affairs-Psychiatry with aspirations of expanding pharmaceutical R&D acumen to compliment 20+ years in preclinical CNS drug discovery.• Supports Lundbeck US Medical Affairs Psychiatry strategies via field based activities aligned with overall corporate goals• Establishes presence with thought leaders and academic institutions in the central north for therapeutic support of Lundbeck psychiatric branded products and targeted disease states, in particular depression and schizophrenia

Managed team of neuropharmacologists providing in vivo biochemical-immunohistochemistry, receptor binding-autoradiography and microdialysis support across pain and CNS programs with focus on compound-driven mechanism of action, target validation and translational strategies.• Established nociceptive biochemical endpoints in behavioral experimental pain models as a complementary strategy for assessing antinociceptive activity contributing to the preclinical development-advancement of candidate pain therapeutics including novel ion channel antagonists• Validated expression of multiple pain discovery targets in animal and human tissues utilizing receptor autoradiography and immunohistochemical confocal microscopy for demonstration of proof-of-concept required for pain program advancement• Established radiometric methodology for assessing nicotinic agonist receptor occupancy linked to preclinical behavioral efficacy-activity in support of dose selection in human clinical studies

Responsible for leading scientists with expertise in immunohistochemistry, in vivo microdialysis and receptor-radioligand imaging to support CNS programs of neurodegenerative and psychiatric disorders with emphasis on Alzheimer’s disease (AD) and schizophrenia.• Demonstrated symptomatic and disease modifying efficacy of histamine H3 receptor antagonists in transgenic mouse models utilizing biochemical markers of cognitive impairment and pathophysiology associated with AD• Established experimental strategy to characterize pharmacological induction of CREB phosphorylation as a biochemical marker of pro-cognition across novel therapeutic classes for potential treatment of AD that included: alpha-7 nicotinic agonists, H3 histamine antagonists and 11β HSD1 inhibitors• Established non-transgenic mouse model of tau hyperphosphorylation that served as a key assay in the advancement of the calpain inhibitor AD program and subsequent AD-related projects

Responsible for providing immunohistochemistry, electrophysiology and in vivo microdialysis support across Neuroscience Discovery CNS programs. Led and coordinated preclinical in vivo behavioral testing for Alpha-7 Nicotinic project.• Demonstrated broad-spectrum efficacy across cognitive domains by alpha-7 agonists leading to development of clinical candidates ABT-107 and ABT-126• Biochemically validated cognitive role of alpha-7 receptor demonstrating antisense knockdown produces spatial memory impairment in rat in support of behavioral efficacy• Established electrophysiological in vivo model of sensory gating deficits associated with schizophrenia reversed by alpha-7 agonists

Led Functional Neurology Lab within Behavioral Neuroscience Group, providing target validation and mechanism studies in support of pain and CNS programs utilizing immunohistochemical and electrophysiological experimental CNS techniques.• Championed use of in vivo antisense knockdown technology in demonstrating role of alpha4-containing nicotinic receptors in nicotinic-mediated antinociception• Established in vivo electrophysiolgical model of absence seizures in effort to identify Depakote backup

Conducted CNS drug discovery research pertaining to elucidation of pharmacological mechanism of action of neuronal nicotinic receptor agonists directed at therapeutic targets in particular pain.• Validated expression of alpha4-containing nicotinic receptors in anatomical regions associated with descending antinociceptive pathways as proof-of-concept finding in support of nicotinic-mediated anlgesisa• Established neuroanatomy-histology lab employing immunhistochemistry for drug discovery of novel neuronal nicotinic agonists as analgesic agents

Established neuroanatomy-histology lab employing immunhistochemistry for drug discovery of novel neuronal nicotinic agonists as analgesic agents.

Headed behavioral pharmacology laboratory for assessing small molecules and peptides in models of obesity, stroke, epilepsy, and cognition.• Championed first in vivo studies with omega conotoxin N-type calcium channel blocker SNX-111 leading to clinical development and approval of Prialt (ziconotide) for management of severe chronic pain.